Review
Copyright ©The Author(s) 2015. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Clin Oncol. Dec 10, 2015; 6(6): 252-263
Published online Dec 10, 2015. doi: 10.5306/wjco.v6.i6.252
Biomarkers in triple negative breast cancer: A review
Budhi S Yadav, Priyanka Chanana, Swaty Jhamb
Budhi S Yadav, Department of Radiotherapy, PGIMER, Chandigarh 160012, India
Priyanka Chanana, Department of Pharmacology, Panjab University, Chandigarh 160012, India
Swaty Jhamb, Dr HS Judge Institute of Dental Sciences, Panjab University, Chandigarh 160012, India
Author contributions: Yadav BS designed and wrote manuscript; Chanana P gathered published studies; Jhamb S reviewed and edited the manuscript.
Conflict-of-interest statement: None.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Correspondence to: Dr. Budhi S Yadav, Associate Professor, Department of Radiotherapy, PGIMER, Sector 12, Chandigarh 160012, India. drbudhi@gmail.com
Telephone: +91-172-2756390 Fax: +91-172-2744401
Received: May 8, 2014
Peer-review started: May 9, 2014
First decision: July 11, 2014
Revised: September 3, 2015
Accepted: October 1, 2015
Article in press: October 8, 2015
Published online: December 10, 2015
Abstract

Breast cancer is an intrinsically heterogeneous disease. In the world about 1 million cases of breast cancer are diagnosed annually and more than 170000 are triple-negative. Characteristic feature of triple negative breast cancer (TNBC) is that it lacks expression of oestrogen, progesterone and human epidermal growth factor receptor-2/neu receptors. They comprise 15%-20% of all breast cancers. We did a systematic review of PubMed and conference databases to identify studies published on biomarkers in TNBC. We included studies with biomarkers including: Epidermal growth factor receptor, vascular endothelial growth factor, c-Myc, C-kit and basal cytokeratins, Poly(ADP-ribose) polymerase-1, p53, tyrosinase kinases, m-TOR, heat and shock proteins and TOP-2A in TNBC. We also looked for studies published on synthetic lethality and inhibition of angiogenesis, growth, and survival pathways. TNBC is a complex disease subtype with many subclasses. Majority TNBC have a basal-like molecular phenotype by gene expression profiling. Their clinical and pathologic features overlap with hereditary BRCA1 related breast cancers. Management of these tumours is a challenge to the clinician because of its aggressive behaviour, poor outcome, and absence of targeted therapies. As the complexity of this disease is being simplified over time new targets are also being discovered for the treatment of this disease. There are many biomarkers in TNBC being used in clinical practice. Biomarkers may be useful as prognostic or predictive indicators as well as suggest possible targets for novel therapies. Many targeted agents are being studied for treatment of TNBC.

Keywords: Triple negative breast cancer, Epidermal growth factor receptor, Vascular endothelial growth factor, p53, Cyclin

Core tip: Triple negative breast cancer (TNBC) are type of breast cancer which lack of estrogen receptors, progesterone receptors and human epidermal growth factor receptor. It is a complex disease subtype with many subclasses. There are many biomarkers in TNBC used for its sub-classification. Clinically-practical assay/biomarkers that can reliably identify TNBC are necessary. Biomarkers may be useful as prognostic or predictive indicators as well as suggest possible targets for novel therapies.